Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3321367 (Anti-TIM-3) +/- Lodapolimab in Advanced Solid Tumors
NCT03099109Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of LY3321367 in solid tumor, sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with Dose-Limiting Toxicities. Started Apr 2017; status: completed.
02
Drugs
LY3321367
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03099109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099109.